Co-ultraPEALut: Role in Preclinical and Clinical Delirium Manifestations
Controlled trialHumansOther animalsWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Controlled trial
- Subjects
- Elderly hip-fracture surgery patients in a single-centre, randomised, single-blind study; number not given in the abstract. Plus mice given lipopolysaccharide as a delirium model
- Dose used in the study
- Glialia (ultramicronised PEA 700 mg plus luteolin 70 mg) in patients; co-ultraPEALut 1 mg/kg by mouth in mice before or after LPS
- Duration
- Not stated in the abstract
- What was measured
- Onset, intensity and duration of postoperative delirium in patients; cognition, locomotion, inflammation, apoptosis and neurotrophins in mice
What the authors reported
Glialia prevented the onset of postoperative delirium and reduced symptom intensity and duration. In mice, the compound improved cognitive and motor outcomes and reduced inflammatory and apoptotic markers.
Limits of this study
Single blind. The abstract gives no patient numbers, no comparator description and no effect sizes. Combined preclinical and clinical report. Several authors have long-standing links with Epitech, which makes Glialia.
Source
PubMed 31210116 · doi:10.2174/1871527318666190617162041
Entry checked against the abstract, supplied by Devlin. Sample size, comparator and duration not in the abstract on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.